Navigation Links
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
Date:2/12/2013

e Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of healthcare products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments).                            
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
6. Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger Sequencing Platform and HLA Typing Kits
7. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
8. Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award
9. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
10. Virtual Ports Receives Patent Approvals in the United States and Japan
11. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... 2011 Reportlinker.com announces that a new ... catalogue: X-ray Equipment - ... http://www.reportlinker.com/p0683628/X-ray-Equipment---Top-5-American-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This package ... the following American countries: United States, Mexico, ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company ... treatment of human viral diseases, today announced the pricing of ... common stock at a public offering price of $6.50 per ... The offering is expected to close on November 21, 2011, ...
Cached Medicine Technology:X-ray Equipment - Top 5 American Markets 2Idenix Pharmaceuticals Prices Public Offering of Common Stock 2
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in ... the holiday season, AlignLife looks forward to their annual toy ... Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as ... are able to give kids toys for Christmas who would ... generosity of our patients." , The 70 toys were donated ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... . All these items are brand new; they are made ... updated with the new range of high quality prom gowns. ... iFitDress.com’s designs are made according to the latest trends. For ... outfit from the company is handpicked by skilled tailors. , ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... the University of Aberdeen in the UK say in a ... linked to increased risk of asthma in kids//. The study ... team showed that low vitamin E in mothers was linked ... ,In this study researchers followed 1,000 children at five years. ...
... village died after eating wild poisonous mushrooms while their mother ... Begma, 8, Neelma, 5, and Jaywanti, 2, died Friday in ... here. ,All the children fell unconscious and died ... 30, managed to survive but is still recovering from food ...
... improve donor lung quality as part of the San ... number of available donor lungs and transplant procedures without ... survival. ,The study appears in the second ... Respiratory and Critical Care Medicine, published by the American ...
... Carolina Wilmington announce the continuation of funding to study ... ultimately// yield treatments. The National Institute of Environmental Health ... to further delve into the acute and chronic effects ... Florida's west coast. ,"Preliminary studies with red ...
... in the Sun's brightness over the past millennium have ... to a review of existing results and new calculations// ... Germany. ,The review, led by Peter Foukal (Heliophysics, ... Among the coauthors is Tom Wigley of the National ...
... the inner lining of the nose are linked to ... current treatments according// to researchers at John Hopkins University. ... the misery of persistent inflammation of the moist tissue ... is clogged passages and recurring infections, according to the ...
Cached Medicine News:Health News:Upgrading Donor Lung Quality to Improve Availability 2Health News:Upgrading Donor Lung Quality to Improve Availability 3Health News:"Beach to Bedside" Study Focuses on Effects of Inhaled Toxins 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 3Health News:Chronic Sinusitis Resulting From Weakene Immune System 2Health News:Chronic Sinusitis Resulting From Weakene Immune System 3
100% Silicone Foley Catheter Kits 2-Way...
ULTRAMER Foley Catheter...
Foley Catheters (Latex) 2-Way...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Medicine Products: